JP2009541220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009541220A5 JP2009541220A5 JP2009515506A JP2009515506A JP2009541220A5 JP 2009541220 A5 JP2009541220 A5 JP 2009541220A5 JP 2009515506 A JP2009515506 A JP 2009515506A JP 2009515506 A JP2009515506 A JP 2009515506A JP 2009541220 A5 JP2009541220 A5 JP 2009541220A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- metformin
- pharmaceutically acceptable
- compound according
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 26
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 16
- 229960003105 metformin Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 208000002249 Diabetes Complications Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 206010012655 Diabetic complications Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 230000000598 lipoate effect Effects 0.000 claims description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 7
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 235000019136 lipoic acid Nutrition 0.000 claims description 6
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012458 free base Substances 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 210000005003 heart tissue Anatomy 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229960004329 metformin hydrochloride Drugs 0.000 claims description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- 238000004467 single crystal X-ray diffraction Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81425006P | 2006-06-16 | 2006-06-16 | |
| PCT/US2007/014034 WO2007149313A1 (en) | 2006-06-16 | 2007-06-14 | Metformin r-(+) lipoate as an antidiabetic agent for control of diabetic hyperglycemia and diabetic complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009541220A JP2009541220A (ja) | 2009-11-26 |
| JP2009541220A5 true JP2009541220A5 (enExample) | 2011-08-18 |
Family
ID=38669506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515506A Withdrawn JP2009541220A (ja) | 2006-06-16 | 2007-06-14 | 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7973073B2 (enExample) |
| EP (1) | EP2046773A1 (enExample) |
| JP (1) | JP2009541220A (enExample) |
| CN (1) | CN101522658A (enExample) |
| AR (1) | AR061500A1 (enExample) |
| CA (1) | CA2691775A1 (enExample) |
| CL (1) | CL2007001759A1 (enExample) |
| IL (1) | IL195959A0 (enExample) |
| TW (1) | TW200816986A (enExample) |
| WO (1) | WO2007149313A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8647612B2 (en) * | 2008-03-05 | 2014-02-11 | Encore Health, Llc | Dithiol compounds, derivatives, and treatment of presbyopia |
| US8697109B2 (en) | 2000-08-16 | 2014-04-15 | Encore Health, Llc | Caged mercaptan and seleno-mercaptan compounds and methods of using them |
| US7914815B2 (en) * | 2000-08-16 | 2011-03-29 | Encore Health, Llc | Method for delivery of pharmaceuticals for treating or preventing presbyopia |
| US20050112113A1 (en) * | 2000-08-16 | 2005-05-26 | Till Jonathan S. | Presbyopia treatment by lens alteration |
| US7935332B2 (en) | 2000-08-16 | 2011-05-03 | Encore Health, Llc | Presbyopia treatment by lens alteration |
| WO2008067403A2 (en) * | 2006-11-28 | 2008-06-05 | Encore Health Llc | Presbyopia treatment by lens alteration |
| US8102027B2 (en) * | 2007-08-21 | 2012-01-24 | Broadcom Corporation | IC package sacrificial structures for crack propagation confinement |
| WO2009111037A2 (en) * | 2008-03-04 | 2009-09-11 | Indigene Pharmaceuticals Inc. | Compositions and methods for treating nos-associated diseases |
| US9044439B2 (en) * | 2008-03-05 | 2015-06-02 | Encore Health, Llc | Low dose lipoic and pharmaceutical compositions and methods |
| WO2009111635A2 (en) | 2008-03-05 | 2009-09-11 | Encore Health, Llc | Dithiol compounds, derivatives, and uses therefor |
| ES2450148T3 (es) * | 2008-06-26 | 2014-03-24 | Laboratorios Silanes, S.A. De C.V. | Una nueva sal de glicinato de metformina para el control de la glucosa en sangre |
| US20100099751A1 (en) * | 2008-10-21 | 2010-04-22 | Al-Mulla Fahd | Method of treating diabetes-related vascular complications |
| WO2010047717A1 (en) * | 2008-10-24 | 2010-04-29 | Biolink Life Sciences, Inc. | Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities |
| EP2442645B1 (en) | 2009-06-15 | 2014-08-27 | Encore Health, Llc | Choline esters |
| DK2442647T3 (en) | 2009-06-15 | 2016-05-30 | Encore Health Llc | Dithiolforbindelser, derivatives thereof, and the uses of these |
| WO2011130719A2 (en) | 2010-04-15 | 2011-10-20 | The Regents Of The University Of Michigan | A biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs |
| IT1399923B1 (it) * | 2010-05-11 | 2013-05-09 | Cbb Net S A | Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono |
| US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| US8440723B2 (en) * | 2011-05-11 | 2013-05-14 | Banavara L. Mylari | Metformin salts of salicylic acid and its congeners |
| US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
| WO2014124141A1 (en) * | 2013-02-07 | 2014-08-14 | Mylari Banavara L | Metformin derivatives for treating diabetes |
| WO2015022613A1 (en) * | 2013-08-11 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US20150073057A1 (en) * | 2013-09-06 | 2015-03-12 | Biokier, Inc. | Composition and method for treatment of diabetes |
| CN106455563A (zh) | 2014-03-03 | 2017-02-22 | 安可视觉公司 | 硫辛酸胆碱酯组合物及使用方法 |
| EP3140316A1 (en) | 2014-05-05 | 2017-03-15 | Thetis Pharmaceuticals LLC | Compositions and methods relating to ionic salts of peptides |
| EP3157936B1 (en) | 2014-06-18 | 2018-10-17 | Thetis Pharmaceuticals LLC | Mineral amino-acid complexes of active agents |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| JP6906047B2 (ja) | 2016-06-03 | 2021-07-21 | テティス・ファーマシューティカルズ・エルエルシー | 特異的炎症収束性メディエーターの塩に関連する組成物及び方法 |
| KR102405239B1 (ko) * | 2017-11-17 | 2022-06-08 | 셀릭스 바이오 프라이빗 리미티드 | 눈 질환 및 피부 질환의 치료를 위한 화합물, 조성물 및 방법 |
| AU2018367909B2 (en) * | 2017-11-17 | 2022-03-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
| CN110037998A (zh) * | 2018-01-16 | 2019-07-23 | 镇学初 | 二甲双胍盐在治疗脑梗死中的用途 |
| CN110294738A (zh) * | 2019-07-22 | 2019-10-01 | 通化师范学院 | 硫辛酸衍生物及其制备方法和用途 |
| CN113105367B (zh) | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
| FR2796551B1 (fr) * | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
| US6693094B2 (en) * | 2001-03-22 | 2004-02-17 | Chrono Rx Llc | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| US20030220301A1 (en) * | 2002-02-14 | 2003-11-27 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
-
2007
- 2007-06-14 US US11/818,909 patent/US7973073B2/en not_active Expired - Fee Related
- 2007-06-14 CA CA002691775A patent/CA2691775A1/en not_active Abandoned
- 2007-06-14 EP EP07796141A patent/EP2046773A1/en not_active Withdrawn
- 2007-06-14 WO PCT/US2007/014034 patent/WO2007149313A1/en not_active Ceased
- 2007-06-14 JP JP2009515506A patent/JP2009541220A/ja not_active Withdrawn
- 2007-06-14 CN CNA2007800302762A patent/CN101522658A/zh active Pending
- 2007-06-15 CL CL200701759A patent/CL2007001759A1/es unknown
- 2007-06-15 AR ARP070102661A patent/AR061500A1/es unknown
- 2007-06-15 TW TW096121712A patent/TW200816986A/zh unknown
-
2008
- 2008-12-15 IL IL195959A patent/IL195959A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009541220A5 (enExample) | ||
| JP6087367B2 (ja) | 三環式化合物、それらを含む組成物およびそれらの使用 | |
| JP5911514B2 (ja) | 脂質低下抗糖尿病薬 | |
| JP2010514832A5 (enExample) | ||
| JP2009084270A5 (enExample) | ||
| TW201726676A (zh) | 降伊波加因鹽非溶劑化物 | |
| BR112015022857B1 (pt) | Sal de omecamtiv mecarbil e processo para preparar sal | |
| TWI721947B (zh) | 抗病毒化合物的固態形式 | |
| JP2010510970A (ja) | ゾレドロン酸の結晶形 | |
| JP2018502101A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2020527175A5 (enExample) | ||
| JP2013541592A5 (enExample) | ||
| RU2002113450A (ru) | Кристаллическая форма (S)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]пропановой кислоты | |
| JP2016512526A (ja) | オナプリストン多形体及び使用方法 | |
| JP2010520176A (ja) | ５−（２，４−ジヒドロキシ−５−イソプロピル−フェニル）−４−（４−モルホリン−４−イルメチル−フェニル）−イソオキサゾール−３−カルボン酸エチルアミドの酸付加塩、水和物および多形、ならびにこれらの形態を含む製剤 | |
| TW200900392A (en) | Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same | |
| RU2008130902A (ru) | Способ получения пиколинатбориновых сложных эфиров | |
| JP2012513443A5 (enExample) | ||
| CA3188286A1 (en) | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate and methods of synthesis | |
| JP2021147392A5 (enExample) | ||
| CN105153066B (zh) | 盐酸沃替西汀的结晶型物及其制备方法 | |
| TWI659041B (zh) | 類固醇樣化合物之多晶型形式以及其製備方法及用途 | |
| IL280891B1 (en) | Treprostinil erbumine salt | |
| CN1109677C (zh) | 氨基苯磺酸衍生物的单水合物及其制备方法 |